TrialJournal of chemotherapy (Florence, Italy)2014

A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin.

Shengli He et al.PubMed ↗Publisher ↗

No numbers read from the abstract.